Verona Pharma Plc ADR (NASDAQ: VRNA) kicked off on Monday, up 7.76% from the previous trading day, before settling in for the closing price of $42.02. Over the past 52 weeks, VRNA has traded in a range of $11.39-$43.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -39.77%. While this was happening, its average annual earnings per share was recorded -200.00%. With a float of $68.91 million, this company’s outstanding shares have now reached $81.83 million.
Let’s determine the extent of company efficiency that accounts for 79 employees. In terms of profitability, gross margin is 80.41%, operating margin of -2370.63%, and the pretax margin is -2352.52%.
Verona Pharma Plc ADR (VRNA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verona Pharma Plc ADR is 15.79%, while institutional ownership is 67.27%. The most recent insider transaction that took place on Dec 05 ’24, was worth 3,205,226. In this transaction President and CEO of this company sold 640,264 shares at a rate of $5.01, taking the stock ownership to the 14,367,552 shares. Before that another transaction happened on Dec 06 ’24, when Company’s President and CEO sold 162,800 for $5.01, making the entire transaction worth $815,400. This insider now owns 14,204,752 shares in total.
Verona Pharma Plc ADR (VRNA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -200.00% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Take a look at Verona Pharma Plc ADR’s (VRNA) current performance indicators. Last quarter, stock had a quick ratio of 13.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 652.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.94, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Looking closely at Verona Pharma Plc ADR (NASDAQ: VRNA), its last 5-days average volume was 0.88 million, which is a drop from its year-to-date volume of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 68.40%. Additionally, its Average True Range was 1.95.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 97.45%, which indicates a significant increase from 90.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.53% in the past 14 days, which was lower than the 52.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.83, while its 200-day Moving Average is $24.45. However, in the short run, Verona Pharma Plc ADR’s stock first resistance to watch stands at $46.82. Second resistance stands at $48.35. The third major resistance level sits at $50.73. If the price goes on to break the first support level at $42.91, it is likely to go to the next support level at $40.53. Now, if the price goes above the second support level, the third support stands at $39.00.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
The company with the Market Capitalisation of 3.71 billion has total of 80,440K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -54,370 K annual income. Company’s last quarter sales were recorded 5,620 K and last quarter income was -42,960 K.
